Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial

Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, works intracellularly within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo‐controlled study evaluated efficacy and safety of apremilast among Japanese patients with moderate to severe plaque psori...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohtsuki, Mamitaro, Okubo, Yukari, Komine, Mayumi, Imafuku, Shinichi, Day, Robert M., Chen, Peng, Petric, Rosemary, Maroli, Allan, Nemoto, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573969/
https://www.ncbi.nlm.nih.gov/pubmed/28391657
http://dx.doi.org/10.1111/1346-8138.13829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573969/
https://www.ncbi.nlm.nih.gov/pubmed/28391657
http://dx.doi.org/10.1111/1346-8138.13829

Ejemplares similares